Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in: Archives of Dermatological Research 4/2016

01-05-2016 | Original Paper

Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting

Authors: Denise Küster, Alexander Nast, Sascha Gerdes, Tobias Weberschock, Gottfried Wozel, Mandy Gutknecht, Jochen Schmitt

Published in: Archives of Dermatological Research | Issue 4/2016

Login to get access

Abstract

Systemic treatments of moderate-to-severe psoriasis differ substantially in terms of effectiveness and costs. Comprehensive economic-evaluations of all systemic treatments for psoriasis from a societal perspective are missing. The objective of our study was to compare the cost-effectiveness all systemic treatments approved for moderate-to-severe psoriasis from a societal perspective, by including all cost categories. An incremental cost-effectiveness-analysis was performed for all systemic treatments for psoriasis, currently recommended by the German S3-Guideline i.e. methotrexate, cyclosporine, fumaric acid esters, and retinoids, adalimumab, etanercept, infliximab and ustekinumab. We used a Markov model with time-dependent transition probabilities and a time horizon of 2 years to investigate incremental cost-effectiveness ratios. Both direct and indirect costs were considered to reflect the societal perspective. Effectiveness outcome was PASI-75 response. One-way and probabilistic sensitivity analyses explored the effect of treatment duration, discount rate, effectiveness, and the perspective (societal vs. healthcare system) on the findings. According to the base-case analysis a cost-effective treatment pathway for moderate-to-severe psoriasis starts with methotrexate, followed by ustekinumab 90 mg and infliximab, if methotrexate does not achieve or maintain PASI-75 response. Sensitivity analyses confirmed the general robustness of these findings with methotrexate being most cost-effective. However, from a third-party-payer perspective (without indirect cost) conventional therapies were generally more cost-effective than biologics. From a value-based healthcare perspective, methotrexate should be the systemic treatment of first choice, ustekinumab 90 mg second choice and infliximab third choice for patients with moderate-to-severe psoriasis. From a societal perspective, the other treatments are less efficient according to our model. From a third-party-payer perspective conventional therapies are more cost-effective than biologics.
Literature
1.
Ahn C, Gustafson C, Sandoval L, Davis S, Feldman S (2013) Cost Effectiveness of Biologic Therapies for Plaque Psoriasis. Am J Clin Dermatol 14:315–326CrossRefPubMed
2.
Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR (2010) Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat 22:65–74CrossRefPubMed
3.
Augustin M, Christina Spehr, Radtke M, Boehncke WH, Thomas Luger, Ulrich Mrowietz, Michael Reusch (2014) German psoriasis registry PsoBest: objectives, methodology and baseline data. JDDG J der Deutschen Dermatologischen Gesellschaft 12:48–57
4.
Boehncke WH, Boehncke S (2008) Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. G Ital Dermatol Venereol 143:307–313PubMed
5.
Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
6.
7.
Briggs AH, Goeree R, Blackhouse G, OBrien BJ (2002) Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Mak 22:290–308CrossRef
8.
Brunner H, Stollenwerk B (2006) 19. Standard-Methoden der gesundheitsökonomischen Bewertung. In: Lauterbach KW, Stock S, Brunner H (eds) Gesundheitsökonomie. Huber, Bern, pp 279–347
9.
Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI (2014) Combined use of systemic agents for psoriasis: a systematic review. JAMA Dermatol 150:1213–1220CrossRefPubMed
10.
11.
Drummond MF, Sculpher MJ, Torrence GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
12.
Drummond M, O’Brien B, Stoddart GL, Torrance G (1998) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
13.
Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J (2003) Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 4:1525–1533CrossRefPubMed
14.
Ferrandiz C, Garcia A, Blasco AJ, Lazaro P (2012) Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 26:768–777CrossRefPubMed
15.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741CrossRefPubMed
16.
Gold MR, Russel LB, Siegel JE, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, Oxford
17.
Hamilton MP, Ntais D, Griffiths CEM, Davies LM (2015) Psoriasis treatment and management—a systematic review of full economic evaluations. Br J Dermatol 172:574–583CrossRefPubMed
18.
Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke WH (2007) Cost-effectiveness of psoriasis therapy with etanercept in Germany. JDDG. Journal der Deutschen Dermatologischen Gesellschaft 5:762–768CrossRefPubMed
19.
20.
21.
Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM (2012) The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 66:e67–e76CrossRefPubMed
22.
Knight C, Mauskopf J, Ekelund M, Singh A, Yang S, Boggs R (2012) Cost-effectiveness of treatment with etanercept for psoriasis in Sweden. Eur J Health Econ 13:145–156CrossRefPubMed
23.
Koopmanshap MA, Utten F, An Ineveld BM, An RL (1995) The friction cost method for measuring indirect cost in disease. J Health Econ 14:171–189CrossRef
24.
Krauth C, Hessel F, Hansmeier T, Wasem T, Seitz R, Schweikert B (2005) Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation—ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). Gesundheitswesen 67:736–746CrossRefPubMed
25.
Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D (2001) The work limitations questionnaire. Med Care 39:72–85CrossRefPubMed
26.
Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S, Erdmann R, Schmitt J, Orawa H, Rzany B, Nast A (2012) Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol 26:1331–1344CrossRefPubMed
27.
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N (2011) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 303:1–10CrossRefPubMedPubMedCentral
28.
29.
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B (2011) S3-guidelines for the treatment of psoriasis vulgaris Update 2011. J Dtsch Dermatol Ges 9(Suppl 2):S1–S104PubMed
30.
31.
Nelson AA, Pearce DJ, Fleischer J, Balkrishnan R, Feldman SR (2008) Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol 58:125–135CrossRefPubMed
32.
Opmeer BC, Heydendael VR, de Borgie CM (2004) Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 140:685–690CrossRefPubMed
33.
Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R (2011) Cost Utility Analysis Based on a Head-to-Head Phase 3 Trial Comparing Ustekinumab and Etanercept in Patients with Moderate-to-Severe Plaque Psoriasis: a Canadian Perspective. Value Health 14:652–656CrossRefPubMed
34.
Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de KP, Rzany B (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(Suppl 2):1–70CrossRefPubMed
35.
Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR (2006) The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatol Treat 17:29–37CrossRef
36.
Portu Sd, Giglio MD, Altomare G, Arcangeli F, Berardesca E, Calzavara Pinton P, Lotti T, Martini P, Peserico A, Simonacci M, Vena GA, Girolomoni G (2010) Cost-effectiveness analysis of TNF-blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. Dermatol Ther 23:S7–S13CrossRefPubMed
37.
Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, Cribier B, Joly P, Jullien D, LeMaitre M, Paul C, Richard-Lallemand MA, Ortonne JP, Aubin F (2010) What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 24(Suppl 2):10–16CrossRefPubMed
38.
Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG (2010) Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatol Treat 22:337–347CrossRef
39.
Ruano J, Isla-Tejera B, Jimnez-Puya R, Rodriguez-Martin A, C + írdenas M, G + ¦mez F, V + ®lez AA, del Prado-Llergo JR, Moreno-Gim + ®nez JC (2013) Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis. Dermatol Ther (Heidelb) 3:131–142
40.
Schmitt J, Ford DE (2006) Limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 213:102–110CrossRefPubMed
41.
Schmitt J, Ford DE (2006) Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 213:102–110CrossRefPubMed
42.
Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A (2014) Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 170:274–303CrossRefPubMed
43.
Schmitt JM, Ford DE (2007) Role of depression in quality of life for patients with psoriasis. Dermatology 215:17–27CrossRefPubMed
44.
Schmitt J, Küster D (2015) Correlation between dermatology life quality index (DLQI) scores and work limitations questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis. Arch Dermatol Res 307:451–453CrossRefPubMed
45.
Schmitt-Rau K, Rosenbach T, Radtke MA, Augustin M (2010) Cost-effectiveness of biological therapy in remission induction of moderate to severe plaque psoriasis. Dermatology 221:236–242CrossRefPubMed
46.
Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K (2007) Costs and quality of life in patients with moderate-to-severe plaque type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 5:209–218CrossRefPubMed
47.
Shear NH, Hartmann M, Toledo-Bahena M, Katsambas A, Connors L, Chang Q, Yao R, Nograles K, Popmihajlov Z (2014) Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol 171:631–641CrossRefPubMed
48.
Singh JA, Wells GA, Christensen R, Tanjong GE, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2:CD008794
49.
Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH (2009) Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 160:1264–1272CrossRefPubMed
50.
Sonnenberg FA, Beck JR (1993) Markov Models in medical decision making: a practical guide. Med Decis Making 13:322–338CrossRefPubMed
51.
Staidle JP, Dabade TS, Feldman SR (2011) A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 12:2041–2054CrossRefPubMed
52.
Umezawa Y, Nobeyama Y, Hayashi M, Fukuchi O, Ito T, Saeki H, Nakagawa H (2013) Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol 40:1008–1013CrossRefPubMed
53.
Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M (2012) Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis. Appl Health Econ Health Policy 10:343–353CrossRefPubMed
54.
Villacorta R, Hay J, Messali A (2013) Cost Effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics 31:823–839CrossRefPubMed
Metadata
Title
Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting
Authors
Denise Küster
Alexander Nast
Sascha Gerdes
Tobias Weberschock
Gottfried Wozel
Mandy Gutknecht
Jochen Schmitt
Publication date
01-05-2016
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 4/2016
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-016-1634-y

Other articles of this Issue 4/2016

Archives of Dermatological Research 4/2016 Go to the issue

Original Paper

Modulation of ROS levels in fibroblasts by altering mitochondria regulates the process of wound healing

Concise Communication

Evaluation of ELISA testing for BP180 and BP230 as a diagnostic modality for bullous pemphigoid: a clinical experience

Letter to the Editor

Commentary on: Sleep disordered breathing and the risk of psoriasis among US women

Review

Does hypoxia play a role in infantile hemangioma?

Original Paper

Intense pulsed light versus photodynamic therapy using liposomal methylene blue gel for the treatment of truncal acne vulgaris: a comparative randomized split body study

Letter to the Editor

Reply to the commentary on: ‘Sleep disordered breathing and the risk of psoriasis among US women’